The role of NPC1L1 in triple-negative breast cancer (TNBC) is increasingly recognized, with studies suggesting its involvement in disease progression through various mechanisms, such as increased cholesterol synthesis, reprogramming of lipid metabolism, sensitivity to PARP inhibitors, and modulation of the immune response [21,22]. This evidence concerns the gene PARP1 and triple-negative breast carcinoma.